Flexibility in therapeutic end points is necessary for the optimal performance of a drug regulatory system. Such flexibility has been manifested in the United States in the past and needs to be assured for the future. Reasons for this are given, and the special case of cancer therapy is discussed.
DelaneyM. The case for patient access to experimental therapy. J Infect Dis.1989;159:416–419.
2.
JusticeACFeinsteinARWellsDK. An effective new prognostic staging system for AIDS. Trans Assoc Am Physicians1988;101:18–23.
3.
CroutJR. The nature of regulatory choices. In: MerrillRAHuttPB, eds. Food and drug law, cases and materials. Mineola, NY: The Foundation Press, Inc; 1987:437–439.
